These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 25041851)

  • 1. Regulators should better leverage effectiveness standards to enhance drug value.
    Naci H; Alexander GC
    Pharmacotherapy; 2014 Oct; 34(10):1005-11. PubMed ID: 25041851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Better medicines for children--where are we now, and where do we want to be?
    Rose K
    Br J Clin Pharmacol; 2005 Jun; 59(6):657-9. PubMed ID: 15948927
    [No Abstract]   [Full Text] [Related]  

  • 3. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.
    van Luijn JC; Gribnau FW; Leufkens HG
    Br J Clin Pharmacol; 2007 Feb; 63(2):159-62. PubMed ID: 17166187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
    Doua JY; Van Geertruyden JP
    Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. To market, to market. The nuts and bolts of prescription drug approval.
    Peterson AM
    Adv Nurse Pract; 2001 Apr; 9(4):87-90. PubMed ID: 12420443
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulatory advice and drug development--a case study in negotiating with regulators.
    Seldrup J
    Stat Med; 2011 Jun; 30(13):1628-35. PubMed ID: 21365671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choice of comparator in active control trials of new drugs.
    van Luijn JC; van Loenen AC; Gribnau FW; Leufkens HG
    Ann Pharmacother; 2008 Nov; 42(11):1605-12. PubMed ID: 18957629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International Conference on Harmonisation; S10 Photosafety Evaluation of Pharmaceuticals; guidance for industry; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2015 Jan; 80(17):4282-3. PubMed ID: 25730921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug development in oncology: a regulatory perspective.
    Augustus S
    Am J Ther; 2011 Jul; 18(4):323-31. PubMed ID: 20335790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specifications from a biotechnology industry perspective.
    Garnick RL
    Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Industry perspectives on ICH guidelines.
    Rockhold FW
    Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for rapid advances in the development of new medicines for special medical needs.
    Milne CP
    Clin Pharmacol Ther; 2014 Jan; 95(1):98-109. PubMed ID: 23917473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence used for approval of new drugs.
    Botstein P
    Isr J Med Sci; 1986; 22(3-4):197-200. PubMed ID: 3528042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Mar; 64(44):10944-7. PubMed ID: 10557618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA implementation of standards developed by the International Conference on Harmonisation.
    Booth PM
    Food Drug Law J; 1997; 52(2):203-23. PubMed ID: 10557561
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulatory issues in pediatric psychopharmacology.
    Laughren TP
    J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1276-82. PubMed ID: 8885581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory watch: Efficiency indicators for new drugs approved by the FDA from 2003 to 2013.
    Belleli R; Fisch R; Szucs TD
    Nat Rev Drug Discov; 2015 Mar; 14(3):156. PubMed ID: 25722232
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessing tumor-related signs and symptoms to support cancer drug approval.
    Williams G; Pazdur R; Temple R
    J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safe drugs and the cost of good intentions.
    Eichler HG; Abadie E; Raine JM; Salmonson T
    N Engl J Med; 2009 Apr; 360(14):1378-80. PubMed ID: 19339718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.